# US 11,433,028 B2 · Compositions for treating viral infections and methods for same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,028 B2
- Document ID: US11433028B2
- Status: Granted
- Kind: B2
- Application number: 17/472,750
- Filed: 2021-09-13
- Published: 2021-12-30
- Granted: 2022-09-06
- Earliest claimed: 2018-12-28
- Assignees: Tiger Development Inc.
- Applicants: Tiger Development, LLC
- Inventors: Jacob Waugh; Jonah Shacknai
- Web page: https://patentgrep.com/patent/US11433028B2

## CPC

- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- C07K 1/00: General methods for the preparation of peptides {, i.e. processes for the organic chemical preparation of peptides or proteins of any length}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compositions containing a protease inhibitor for treating viral infections and methods for treating a patient before, during, or after exposure to an infectious agent by administering such compositions are described herein.

## Claims

### Claim 1

A method for treating COVID-19 infection comprising administering to a subject in need of treatment a composition selected from the group consisting of polylysine, α-polylysine, and ε-polylysine and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The method of claim 1, wherein administering is carried out by topical administration to an eye, ear, or nose of the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein administering is carried out by intranasal spray.

### Claim 4 (depends on 1)

The method of claim 1, further comprising repeating administering at least once per day.

### Claim 5 (depends on 1)

The method of claim 1, wherein administering reduces viral load in patient sputum or blood plasma by at least about 20%.

### Claim 6 (depends on 1)

The method of claim 1, wherein administering improves time to recovery by at least about 20%.

### Claim 7 (depends on 1)

The method of claim 1, wherein administering reduces long term effects of COVID-19.

### Claim 8 (depends on 1)

The method of claim 1, wherein the polylysine, α-polylysine, and ε-polylysine comprises an amino acid sequence selected from the group consisting of RGRR (SEQ ID NO:1), RKRKKR (SEQ ID NO:2), RKKR (SEQ ID NO:3), RRRKKR (SEQ ID NO:4), and combinations thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition further comprises an antiviral agent or anti-inflammatory agent.

### Claim 10 (depends on 1)

The method of claim 1, further comprising administering an antiviral agent or an anti-inflammatory agent with the composition.

### Claim 11 (depends on 10)

The method of claim 10, wherein administering the antiviral agent on anti-inflammatory agent is carried out simultaneously or sequentially with the composition.

### Claim 12 (depends on 10)

The method of claim 10, wherein administering the antiviral agent or anti-inflammatory agent is carried out by oral administration or injection.